肾透明细胞癌血浆miR-210、miR-378的表达及临床意义

李东亮; 舒博; 唐双阳; 毕兴; 陈鹏

doi:10.13201/j.issn.1001-1420.2015.10.009

肾透明细胞癌血浆miR-210、miR-378的表达及临床意义

- 新疆医科大学附属肿瘤医院泌尿外科(乌鲁木齐, 830011)
基金项目:
乌鲁木齐市科技基金(编号Y131310005)

详细信息

通讯作者: 毕兴,E-mail:44272603@qq.com; 陈鹏

中图分类号: R737.11

收稿日期: 2015-06-08

Expression of plasma miR-210, miR-378 and theirs clinical significance in renal clear cell carcinoma

- Department of Urology, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, 830011, China

More Information

Corresponding authors: BI Xing ; CHEN Peng

Received Date: 08 June 2015

摘要

摘要: 目的:分析肾透明细胞癌患者和健康人群中循环miR-210和miR-378表达差异及其临床意义。方法:收集肾透明细胞癌患者和健康人群血液标本分别为22例和20例。采用实时荧光定量聚合酶链反应(Real-time PCR)检测miR-210 和miR-378在肾透明细胞癌患者和健康人群血浆的表达水平,分析其表达水平与临床病理特征的关系。结果:miR-210、miR-378在肾透明细胞癌患者血浆中表达值[(1.76±1.88)、(0.21±0.19)]显著高于其健康人群中的表达值[(0.55±0.79)、(0.04±0.05)],差异有统计学意义(P<0.05)。miR-210的表达水平与肿瘤的病理分期(TNM分期)有关 (P<0.05);而与患者性别和年龄、民族、肿瘤大小和病理核分级(Furman分级)无明显关系(P>0.05)。而miR-378的表达水平与患者性别和年龄、民族、肿瘤大小、病理分期和病理核分级无明显关系(P>0.05)。miR-210和miR-378在诊断肾透明细胞癌的AUC分别为0.803和0.802(P<0.05)。灵敏度分别为0.818和0.682,特异度分别为0.80和0.90。结论:血浆miR-210、miR-378与肾透明细胞癌的发生发展有关,可能成为肾透明细胞癌的筛查诊断的生物学指标。
- 肾透明细胞癌 /
- 实时荧光定量 /
- miRNAs /
- 血浆
Abstract: Objective:To investigate the difference of plasma miR-210 and miR-378 expression between patients with renal clear cell carcinoma and healthy people, and evaluate the clinical significance.Method:We collected blood specimens from 22 renal clear cell carcinoma patients and 20 healthy people. The level of plasma miR-210 and miR-378 were quantified by real-time reverse transcriptase polymerase chain reaction (Real-time PCR), and the relationship between miR-210, miR-378 level and clinical and pathological factors was explored.Result:The expression of plasma miR-210 and miR-378 in renal clear cell carcinoma[(1.76±1.88), (0.21±0.19)] was significantly higher than that in the healthy people[(0.55±0.79), (0.04±0.05)]. The difference was statistically significant (P<0.05). The high expression of miR-210 was associated with pathological stage (TNM stage) (P<0.05). There was no statistical difference of the expression of miR-210 among different genders, ages, nations, tumor sizes and Furman grades by the statistical analysis (P>0.05). The high expression of miR-378 was not associated with gender, age, nation, tumor size, pathological stage and Furman grade by the statistical analysis (P>0.05). The study show that plasma miR-210 and miR-378 have significant diagnostic value for renal clear cell carcinoma. MiR-210 showed the areas under the ROC curve was 0.803 (P<0.05) with 81.8% in sensitivity and 80.0% in specificity, and miR-378 showed the areas under the ROC curve was 0.802 (P<0.05) with 68.2% in sensitivity and 90.0% in specificity.Conclusion:Plasma miR-210 and miR-378 play a role in the development and progression of renal clear cell carcinoma and may be potential biomarkers in the screening diagnosis of renal clear cell carcinoma.
- renal clear cell carcinoma /
- RT-PCR /
- miRNAs /
- plasma

HTML全文

参考文献(18)

[1]	Manikandan J, Aarthi J J, Kumar S D, et al. Oncomirs:The potential role of non coding MicroRNAs in understanding cancer[J]. Bioinformation, 2008, 2(8):330-334.
[2]	Eble J N, Sauter G, Epstein J I, et al. Pathology and genetics tumours of the urinary system and male genital organs[M]. Lyoh:International Agency for Research on Cancer, 2004:4-6.
[3]	L jungberg B. Prognostic factors in renal cell carcinoma[J]. Scand J Surg, 2004, 93(2):118-125.
[4]	Zhao A, Li G, Péoc'h M, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma[J]. Exp Mol Pathol, 2013, 94(1):115-120.
[5]	Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma[J]. J Transl Med, 2012, 10:55.
[6]	Redova M, Poprach A, Besse A, et al. miR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma[J]. Tumour Biol, 2013, 34(1):481-491.
[7]	Grosso S, Doyen J, Parks S K, et al. MiR-210 promotes a hypoxic phenotype and increases radio resistance in human lung cancer cell lines[J]. Cell Death Dis, 2013, 4:e544.
[8]	Cai H, Lin L, Cai H, et al. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma[J]. Med Oncol, 2013, 30(2):499.
[9]	Rotkrua P, Shimada S, Mogushi K, et al. Circulating microRNAs as biomaikers for early detection of diffuse-type gastric cancer using a mouse model[J]. Br J Cancer, 2013, 108(4):932-940.
[10]	Chen W Y, Liu W J, Zhao Y P, et al. Induction, modulation and potential targets of miR-210 in pancreatic cancer cells[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(3):319-324.
[11]	Ota T, Doi K, Fujimoto T, et al. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells[J]. Anticancer Res, 2012, 32(6):2271-2275.
[12]	Yang W, Sun T, Cao J, et al.Down regulation of miR-210 expression inhibits prolife ration,induces apoptosis and enhances radio sensitivity in hypoxic human hepatoma cells in vitro[J]. Exp Cell Res, 2012, 318(8):944-954.
[13]	Toyama T, Kondo N, Endo Y, et al. High expression of microRNA-210 is an in-dependent factor indicating a poor prognosis in Japanese trip lenegative breast cancer patients[J]. Jpn J Clin Oncol, 2012, 42 (4):256-263.
[14]	Lee C H, Subramanian S, Beck A H, et al. MicroRNA profiling of BRCA1/2 mutation carrying and non-mutation carrying high grade serous carcinomas of ovary[J]. PLoS One, 2009, 4(10):e7314.
[15]	Skrzypek K, Tertil M, Golda S, et al. Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis[J]. Antioxid Redox Signal, 2013, 19(7):644-660.
[16]	Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles:artefacts no more[J]. Trends Cell Biol, 2009, 19(2):43-51.
[17]	Jung M, Mollenkopf H J, Grimm C, et al. MicroRNA profiling of clear cell renal cell Cancer identifies a robust signature to define renal malignancy[J]. J Cell Mol Med, 2009,13(9B); 3918-3928.
[18]	周亮, 冷慧敏, 翟庆娜, 等. 肾癌中miR-210的异常表达及意义[J]. 中国实验诊断学, 2012, 3(16):468-471.